Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TY-0609
- Development stage
- Preclinical
- Lead developer
- TYK Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TY-0609 is a selective small molecule inhibitor of Cyclin-dependent kinase 4 (CDK4) currently in preclinical development by Zhejiang Tongyuan Kang Medicine (TYK Medicines). CDK4 is a key regulator of the cell cycle, specifically the transition from the G1 to the S phase, and its overactivation is frequently observed in various solid tumors. By selectively targeting CDK4, TY-0609 aims to inhibit tumor cell proliferation while potentially offering a differentiated safety or efficacy profile compared to non-selective CDK4/6 inhibitors. The program is currently being evaluated for the treatment of solid tumors.
- Other names
- TY-0609TY0609TY 0609
02
Targets
CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on TY-0609.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TY-0609.